Pharmacy World and Science

, Volume 19, Issue 2, pp 82–88 | Cite as

Lifestyle, fibrinolysis and lipids.

  • E.J.P Brommer
  • J.A. Gevers Leuven
  • P. Brakman


Lifestyle including eating habits, physical training, smoking, drinking alcoholic beverages etc. can to a certain extent maintain or spoil our health. The physiological mechanisms of haemostasis and of lipoprotein metabolism play a role in acute cardiovascular diseases but also in a great number of chronic diseases in which vascular pathology is prominent. Impaired fibrinolysis and increased lipid levels are often incriminated in vascular disease. Lifestyle can modify fibrinolysis as well as lipid levels. Physical training, moderate eating habits, no smoking, moderate alcohol intake will be a beneficial influence on both fibrinolysis and lipid levels. The possibility that long‐term pharmacological intervention may adversely affect fibrinolysis and lipid levels should always be considered.

Lipids Fibrinolysis Lifestyle vascular disease Atheroselerosis Thrombosis Oestrogens 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Balliere's Clin Haematol 1995;8:291‐321.Google Scholar
  2. 2.
    Van Hinsbergh VWM. Role of thrombin and plasminogen activators, essential proteases of the coagulation and fibrinolysis cascade in fibrin homeostasis and vascular cell activation. In: Catravas JD. et al, editors. Vascular endothelium: Responses to injury. New York: Plenum Press, 1996.Google Scholar
  3. 3.
    Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell t‐PA synthesis and release. Int J Hematology 1994,59:233‐55.Google Scholar
  4. 4.
    Kooistra T, Lansink M, Emeis JJ. Stimulators of tissue‐type plasminogen activator. Drugs of the Future 1996;21(3):291‐9.Google Scholar
  5. 5.
    Quax PHA, Koolwijk P, Verheijen JH and Van Hinsbergh VWM. The role of plasminogen activators in vascular pericellular proteolysis. In: van Hinsbergh VMM, editor. Vascular control of haemostasis. Camberwell Australia: Harwood Academic Publishers, 1995:227‐45.Google Scholar
  6. 6.
    Ogston D. Antifibrinolytic drugs. Chichester: John Wiley & Sons, 1984.Google Scholar
  7. 7.
    Schleef RR, Higgins DL, Pillemer E, Levitt, LJ. Bleeding diathesis due to decreased functional activity of type I plasminogen activator inhibitor. J Clin Invest 1989;83:1747‐52.Google Scholar
  8. 8.
    Boman K, Hellsten G, Bruce A, Hallmans G, Nilsson TK. Endurance physical activity, diet and fibrinolysis. Atherosclerosis 1994 Mar;106(1):65‐74.Google Scholar
  9. 9.
    Williams RS, Logue EE, Lewis JI, Bardon T, Stead NW, Wallace AG, Pizzo SV. Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. New Engl J Med 1980;302:987‐91.Google Scholar
  10. 10.
    Willich SN, Lewis M, LÖwel H, Arntz HR, Schubert F, Schröder R. Physical exertion as a trigger of acute myocardial infarction. New Eng J Med 1993;329:1684‐90.Google Scholar
  11. 11.
    Van den Burg PJM. Thesis, Utrecht, 1994.Google Scholar
  12. 12.
    Huisveld IA, van den Burg PJM, van Vliet M, Hospers JEH, Mosterd WL. The urokinase‐type, rather than the tissue‐type plasminogen system is influenced by regular physical training. Fibrinolysis 1994;8(suppl):13(abstract).Google Scholar
  13. 13.
    Suzuki T, Yamauchi K, Yamada Y, Furumichi T, Furui H, Tsuzuki J, Hayashi H, Sotobata I, Saito H. Blood coagulability and fibrinolytic activity before and after physical training during the recovery phase of acute myocardial infarction. ClinCardiol 1992;15(5):358‐64.Google Scholar
  14. 14.
    Speiser W, Langer W, Pschaick A, Selmayr E, Ibe B, Nowacki PE, Müller‐Berghaus G. creased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program Thromb Res 1988;51:543‐55.Google Scholar
  15. 15.
    Potter van Loon BJ, Heere LP, Kluft C, Briet E, Dooijewaard G, Meinders AE. Fibrinolytic system during long‐distance running in IDDM patients and in healthy subjects. Diabetes‐Care 1992 Aug;15(8):991‐6.Google Scholar
  16. 16.
    Van den Burg PJ, Dooijewaard G, Van Vliet M, Mosterd WL, Kluft DC, Huisveld IA. Differences in u‐PA and t‐PA increase during acute exercise: relation with exercise parameters. Thromb Haemost 1994 Feb;71(2):236‐9.Google Scholar
  17. 17.
    Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC, et al. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol 1992 Jun;19(7):1412‐20.Google Scholar
  18. 18.
    De Geus EJ, Kluft C, de Bart AC, van Doornen LJ. Effects of exercise training on plasminogen activator inhibitor activity. Med Sci Sports Exerc 1992 Nov;24(11):1210‐9.Google Scholar
  19. 19.
    Urano T, Cho M, Takahashi S, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada A. Changes of parameters in fibrinolytic system caused by mental stress. Thromb Res 1990;60:501‐7.Google Scholar
  20. 20.
    MacFarlane RG, Biggs R. Observations on fibrinolysis. Spontaneous activity associated with surgical operation, trauma etc The Lancet 1945;II:862‐3.Google Scholar
  21. 21.
    Jern Ch, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes in plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemostas 1989;62:767‐71.Google Scholar
  22. 22.
    Rankinen T, RT Rauramaa R, Vaisanen S, Penttila IM, Uusitupa M. Relation of habitual diet and cardiorespiratory fitness to blood coagulation and fibrinolytic factors. Thromb Haemost 1994 Feb;71(2):180‐3.Google Scholar
  23. 23.
    Marckmann P, Sandstrom B, Jespersen J. Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. Atherosclerosis. 1993(a) Jul;101(2):225‐34.Google Scholar
  24. 24.
    Marckmann P, Sandstrom B, Jespersen J. Favorable long‐term effect of a low‐fat/high‐fiber diet on human blood coagulation and fibrinolysis. Arterioscler Thromb 1993(b);13(4):505‐11.Google Scholar
  25. 25.
    Hellsten G, Boman K, Saarem K, Hallmans G, Nilsson TK. Effects on fibrinolytic activity of corn oil and a fish oil preparation enriched with omega‐3‐polyunsaturated fatty acids in a long‐term study. Curr Med Res Opin 1993;13(3):133‐9.Google Scholar
  26. 26.
    Boberg M, Pollare T, Siegbahn A, Vessby B. Supplementation with n‐3 fatty acids reduces triglycerides but increases PAI‐1 in non‐insulin‐dependent diabetes mellitus. Eur J Clin Invest 1992 Oct;22(10):645‐50.Google Scholar
  27. 27.
    Moller JM, Svaneborg N, Lervang HH, Varming K, Madsen P, Dyerberg J, Schmidt EB. The acute effect of a single very high dose of N‐3 fatty acids on coagulation and fibrinolysis. Thromb Res 1992 Sep 1;67(5):569‐77.Google Scholar
  28. 28.
    Pan WH, Chin ChJ, Shev ChT, Lee MH. Hemostatic factors and blood lipids in young Buddhist vegetarians and omnivores. Am J Clin Nutr 1993;58:354‐9.Google Scholar
  29. 29.
    Allen R. The effect of poly‐lysine on the activation of plasminogen. In: Davidson JF, Nilsson IM, Astedt B, editors, Churchill Livingstone Publisher. Progress in Fibrinolysis Vol V. 1981:134‐8.Google Scholar
  30. 30.
    Sumi H, Kawabe K, Nakajima N. Effect of various polyamino acids and D‐and L‐amino acids on the blood fibrinolytic system. Comp Biochem Physiol B 1992 May;102(1):159‐62.Google Scholar
  31. 31.
    Legnani C, Palareti G, Biagi R, Poggi M, Ludovici S, Babini AC, Baraldi L, Parenti M, Coccheri S. A 3 month period of very low calorie diet (VLCD) in highly obese subjects reduces the levels of factor VII and PAI but not fibrinogen. Thromb Haemostas 1994;69:1067(abstract).Google Scholar
  32. 32.
    Sylvan A, Rutegard JN, Janunger KG, Sjolund B, Nilsson TK. Normal plasminogen activator inhibitor levels at long‐term follow‐up after jejuno‐ileal bypass surgery in morbidly obese individuals. Metabolism 1992 Dec;41(12):1370‐2.Google Scholar
  33. 33.
    Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor‐1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet‐Med 1993 Aug‐Sep;10(7):638‐42.Google Scholar
  34. 34.
    Seljeflot I, Eritsland J, Torjesen P, Arnesen H. Insulin and PAI‐1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest 1994 May;54(3):241‐6.Google Scholar
  35. 35.
    Juhan‐Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996;10:127‐36.Google Scholar
  36. 36.
    Hendriks HF, Veenstra J, Velthuis te Wierik EJ, Schaafsma G, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. BJM 1994 Apr 16;308(6935):1003‐6.Google Scholar
  37. 37.
    Allen RA, Kluft C, Brommer EJP. A chronic effect of smoking on fibrinolysis. In: Davidson‐JF, Bachmann F, Bouvier CA, Kruithof EKO, editors. Churchill Livingstone Publisher. Progress in fibrinolysis Vol 6. 1983:73‐5.Google Scholar
  38. 38.
    Allen R, Kluft C, Brommer EJP. Acute effect of smoking on fibrinolysis: increase in the activity of circulating extrinsic (tissue‐type) plasminogen activator. Eur J Clin Invest 1984;14:354‐61.Google Scholar
  39. 39.
    Oudenhoven LFIJ, Brommer EJP, Aronson DC, Raben AMTJ, FrÖhlich M, van Bockel JH. Impaired fibrinolysis in young adults with arterial occlusive disease: the relationship with hyperinsulinaemia and smoking. Fibrinolysis 1994;8:263‐9.Google Scholar
  40. 40.
    Brommer EJP, Derkx FHM, Barrett‐Bergshoeff MM, Schalekamp MADH. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII‐antigen to infusion of DDAVP. Thromb Haemostas 1984;51:42‐4.Google Scholar
  41. 41.
    Brommer EJP, Derkx FHM, Barrett‐Bergshoeff MM, Schalekamp MADH. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII‐antigen to infusion of DDAVP. Thromb Haemostas 1984;51:42‐4.Google Scholar
  42. 42.
    SpÖttl F, Holzknecht F, Braunsteiner H. Inhibitors of the plasminogen‐activation in patients with primary 'carbohydrateinduced' hypertriglyceridemia J Atheroscl Res 1968;8:821‐6.Google Scholar
  43. 43.
    Epstein SE, Rosing DR, Brakman P, Redwood DR, Astrup T. Impaired fibrinolytic response to exercise in patients with type‐IV hyperlipoproteinemia. The Lancet 1970;ii:631‐4.Google Scholar
  44. 44.
    Brommer EJP, Gevers Leuven JA, Barrett‐Bergshoeff MM, Schouten JA. Response of fibrinolytic activity and factor VIII‐reated antigen to stimulation with desmopressin in hyperlipoproteinemia. J Lab Clin Med 1982;100:105‐14.Google Scholar
  45. 45.
    Brommer EJP, Verheijen JH, Chang GTG, Rijken DC. Masking of fibrinolytic response to stimulation by an inhibitor of tissue‐typing plasminogen activator in plasma. Thromb Haemostas 1984;52:154‐6.Google Scholar
  46. 46.
    Brussaard HE, Gevers Leuven JA, Krans HMJ, Meyer P, Buytenhek R, Kluft C. Non‐esterified fatty acids are related with hypofibrinolysis in Type 2 diabetes mellitus. Fibrinolysis 1994;8: Suppl 2:25‐7.Google Scholar
  47. 47.
    Bahru Y, Kesteven P, Alberti KG, Walker M. Decreased plasminogen activator inhibitor‐1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabet‐Med. 1993 Nov;10(9):802‐6.Google Scholar
  48. 48.
    Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg‐AL. Lp(a) lipoprotein as a risk of myocardial infarction. JAMA 1986;256:2540‐4.Google Scholar
  49. 49.
    Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and risk of myocardial infarction. JAMA 1993;270:2195‐9.Google Scholar
  50. 50.
    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone‐replacement in postmenopausal women. New Eng J Med;1993:328:1069‐75.Google Scholar
  51. 51.
    Gevers Leuven JA, van der Mooren MJ, Buytenhek M. Effect of the progestogen medrogestone on plasma lipoprotein levels in postmenopausal women using conjugated estrogens: an open, randomized comparative study. Fert steril 1995;64:525‐8.Google Scholar
  52. 52.
    Consensus Conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080‐6.Google Scholar
  53. 53.
    Kannel WB, Dawber TR, Friedman GD, Glennon WE, Mc Namara PM. Risk factors in coronary heart disease. Annals Int. Med. 1961;61:888‐99.Google Scholar
  54. 54.
    Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Annals Int Med. 1990;112:780‐92.Google Scholar
  55. 55.
    Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Brit Med J 1993;306:1367‐73.Google Scholar
  56. 56.
    Rimm EB, Giovannucci EL, Willett WC, Coldits GA, Ascherio A, Rosner B, Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in man. Lancet 1991;338:464‐8.Google Scholar
  57. 57.
    Shaper AG, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining the U‐shaped curve. Lancet 1988;2:1267‐73.Google Scholar
  58. 58.
    Curfman GD. Is exercise beneficial‐or hazardous‐to your heart? New Eng J Med 1993;329:1730‐1.Google Scholar
  59. 59.
    Manninen V, Tenkanen L, Koskinen P, Huttunen JK, MÄnttÄri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study Circulation 1992;85:37‐45.Google Scholar
  60. 60.
    Weintraub MS, Zechner R, Risenberg S, Breslow JL. Dietary polyunsaturated fats of the W‐6 and W‐3 series reduce postprandial lipoprotein levels. J Clin Invest 1988;82:1884‐93.Google Scholar
  61. 61.
    Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and apolipoprotein levels. New Eng J Med 1988;318:1244‐8.Google Scholar
  62. 62.
    Sirtori CR, Tremoli E, Gatti E, Montanari G, Sirtori M, Colli S, Gianfranceschi G, Maderna P, Zucchi Dentone C, Testolin G, Galli C. Controlled evaluation of fat intake in the mediterranean diet: comparative activities of olive and corn oil on plasma lipids and platelets in high risk patients. Am J Clin Nutr 1986;44:635‐42.Google Scholar
  63. 63.
    Gevers Leuven JA, Dersjant‐Roorda MC, Helmerhorst FM, de Boer R, Neymeyer‐Leloux A, Havekes L. Estrogenic effect of gestodene‐or desogestrel‐containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol 1990;163:1 part 2:358‐62.Google Scholar
  64. 64.
    Gevers Leuven JA, Kluft C, Dersjant‐Roorda MC, HarthoornLasthuizen EJ, de Boer R, Helmerhorst FM. Effects of low dose oral contraceptives differing in progestogen compound on coagulation and fibrinolytic risk variables for venous and arterial thromboembolic diseases. In: Glas‐Greenwalt, P. editor. Fibrinolysis and disease, molecular and hemovascular aspects of fibrinolysis, chapter 32, CRC Press, 1995:226‐234.Google Scholar
  65. 65.
    Gevers Leuven JA. Sex steroids and lipoprotein metabolism. Pharmac Ther 1994;64:99‐126.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • E.J.P Brommer
    • 1
  • J.A. Gevers Leuven
    • 1
  • P. Brakman
    • 1
  1. 1.Gaubius Laboratory TNO‐PGLeidenThe Netherlands

Personalised recommendations